56663-75-3

Usage

Uses

Used in Organic Synthesis:
3-CHLORO-2,2-DIMETHYL-BUT-3-ENOIC ACID is used as a synthetic building block for the creation of more complex organic molecules. Its application in organic synthesis is due to its reactivity and the ability to form a wide range of derivatives, making it a versatile compound for the development of new materials and pharmaceuticals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 3-CHLORO-2,2-DIMETHYL-BUT-3-ENOIC ACID is used as an intermediate in the synthesis of various drugs. Its unique structure allows for the development of new drug candidates with potential therapeutic applications, contributing to the advancement of medical treatments.
Used in Chemical Research:
3-CHLORO-2,2-DIMETHYL-BUT-3-ENOIC ACID is also employed in chemical research as a model compound to study various reaction mechanisms and to understand the behavior of similar molecules. This helps researchers to develop new synthetic methods and improve existing ones, ultimately leading to more efficient and environmentally friendly chemical processes.

Upstream product

• 597-04-6 ethyl 2,2-dimethyl-3-oxobutanoate 
• 56663-74-2 methyl 3-chloro-2,2-dimethylbut-3-enoate 
• 97987-62-7 3-Chloro-2,2-dimethyl-but-3-enoic acid ethyl ester 
• 38923-57-8 methyl 2,2-dimethyl-3-oxobutanoate 

Downstream Products

• 95924-34-8 2,2-dimethyl-3-butynoic acid methyl ester 
• 188990-87-6 4-(6-Benzyloxy-pyridin-2-yl)-2,2-dimethyl-but-3-ynoic acid 
• 188990-86-5 4-(6-Benzyloxy-pyridin-2-yl)-2,2-dimethyl-but-3-ynoic acid methyl ester 
• 52066-34-9 3,3-dimethyl-pent-4-yn-2-one 
• 952665-08-6 methyl 4-(2-amino-5-nitrophenyl)-2,2-dimethylbut-3-ynoate 
• 952665-09-7 methyl 4-(2-butyramido-5-nitrophenyl)-2,2-dimethylbut-3-ynoate 

Relevant academic research and scientific papers

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette ('ABC') transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ('CFTR'). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

Modulators of ATP-binding cassette transporters

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

Acid-amide intermolecular hydrogen bonding

A 2,2-dimethylbutynoic acid with a pyridone terminus (1) acts as its self-complement in molecular recognition to form an intermolecularly hydrogen-bonded dimer with hydrogen bonding between the amide and carboxylic acid group. The dimer is found in crystals of 1 by X-ray diffraction, in chloroform solution by 1H-NMR experiments and vapor pressure osmometry, and in the gas phase by FAB-MS.

Studies in Decarboxylation. Part 15. The Effect of 3-Substitution on the Rate of Decarboxylation of βγ-Unsaturated Acids

The kinetic effect of substituents at C(3) of βγ-unsaturated acids is consistent with the development of a partial positive charge at that position during decarboxylation.The OMe group increases the rate of decarboxylation as much as 105-106 fold.